« prev   random   next »



By mell following x   2017 Nov 3, 7:37am 1,398 views   15 comments   watch   sfw   quote     share    

Just received CRL from FDA for XYOSTED, their injectable testosterone, price crashed from almost $4 to sub $2. 50MM+ sales and rising, possible approval of generic epi-pen version in partnership w/ TEVA (ATRS supplies injectors). Risks are possible dilution (already bloated share count) if turnaround to profitability is delayed too much, otherwise this should slowly churn towards profitability within the next 1-2 years. Any movement on the CRL without the requirement of additional trials or approval of TEVAs generic epi-pen will send this soaring. Market cap just below 300MM, target market cap 700MM-1bln.

1   mell   ignore (2)   2018 Feb 14, 3:48pm   ↑ like (0)   ↓ dislike (0)   quote        

AMAG just got approval in partnership with ATRS for Makena injection. up $20-30% from it's sub $2 lows. Good stock going forward. More news to come as they meet with FDA 02/21 wrt Xyosted CRL.
2   HEYYOU   ignore (16)   2018 Feb 14, 6:19pm   ↑ like (0)   ↓ dislike (0)   quote        

Real men sweat testosterone!
3   mell   ignore (2)   2018 Mar 5, 11:16am   ↑ like (1)   ↓ dislike (0)   quote        

Would like to put ATRS back on the radar. They had a relatively confident presentation today and many possible catalysts are looming such as update on FDA meeting wrt XYOSTED (update should come within the next few weeks) as well as TEVA generic EpiPen launch news this year (which ATRS is partnered with supplying the injectors). Could be a great year for this biotech turning towards profitability, currently trading around $2.20.
4   mell   ignore (2)   2018 May 11, 9:41pm   ↑ like (1)   ↓ dislike (0)   quote        

Still in this (from the low $2s), accumulated sizable position, swing-trading around the core. $2.50 now, looking for a double, or at least $4. Best case scenario XYOSTED approval (September) and generic Epipen approval (TEVA partnered with ATRS) could bring $10. Downside $2, hardly lower, since they already have growing earnings with their currently approved products. Currently there's a shortage of Epipens, so the FDA could approve TEVA's generic version soon.
5   mell   ignore (2)   2018 May 12, 2:12pm   ↑ like (1)   ↓ dislike (0)   quote        


"Expedite the FDA’s review of the Abbreviated New Drug Application from Teva Pharmaceuticals for approval of its proposed AB-rated generic epinephrine, using Antares Pharma Inc’s Vibex®auto-injector."
6   Patrick   ignore (0)   2018 May 12, 6:17pm   ↑ like (2)   ↓ dislike (0)   quote        

I have 5000 shares, bought at $2.37 about a month ago. Up more than 6%, but happy to ride out whatever happens for a few years. I need a little excitement so I have something to watch every day. Most of my other stocks are pretty boring.
7   TwoScoopsOfWompWomp   ignore (2)   2018 May 12, 6:42pm   ↑ like (1)   ↓ dislike (0)   quote        

I'll gonna go in for a couple of thousand...
8   Patrick   ignore (0)   2018 May 12, 7:08pm   ↑ like (1)   ↓ dislike (0)   quote        

Now we can all watch this thing and comment. Should have some entertainment value at least.
9   mell   ignore (2)   2018 May 12, 7:23pm   ↑ like (0)   ↓ dislike (0)   quote        

lol made decent bank last year with my picks, but now the peer pressure is on! Betting big on this, that epipen shortage needs to be dealt with rather swiftly. And while the ways of the FDA can be rather mysterious I do think they may get moving on this soon ;)
10   Patrick   ignore (0)   2018 May 12, 7:25pm   ↑ like (2)   ↓ dislike (0)   quote        

Don't worry, I accept the risk of my bet. No one made me do it.
11   mell   ignore (2)   2018 May 17, 9:41am   ↑ like (1)   ↓ dislike (0)   quote        

Train has left the station, @TwoScoopsOfDragonEnergy you're in? Scoops and Patrick, enjoy the ride ;)
12   TwoScoopsOfWompWomp   ignore (2)   2018 May 17, 9:52am   ↑ like (1)   ↓ dislike (0)   quote        

Thanks for the reminder @mell. Just wrote the broker. Just in for a thousand bucks, I got a baby ready to drop out any second so I'm keeping some cash around.
13   mell   ignore (2)   2018 May 31, 8:41am   ↑ like (0)   ↓ dislike (0)   quote        

$2.70 this am. Looking good here my fellow Antarians.
14   mell   ignore (2)   2018 Jun 13, 7:51am   ↑ like (2)   ↓ dislike (0)   quote        

$2.95. Chart looks terrific.

The Housing Trap
You're being set up to spend your life paying off a debt you don't need to take on, for a house that costs far more than it should. The conspirators are all around you, smiling to lure you in, carefully choosing their words and watching your reactions as they push your buttons, anxiously waiting for the moment when you sign the papers that will trap you and guarantee their payoff. Don't be just another victim of the housing market. Use this book to defend your freedom and defeat their schemes. You can win the game, but first you have to learn how to play it.
115 pages, $12.50

Kindle version available

about   best comments   contact   one year ago   suggestions